|
|
|
|
Дата |
|---|
| 21:58 |
| 25.08.2026 |
| 24.08.2026 |
| 21.08.2026 |
| 20.08.2026 |
| 19.08.2026 |
| 18.08.2026 |
| 17.08.2026 |
| 14.08.2026 |
| 13.08.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
12.44
|
12.61
|
12.20
|
11.78
|
12.54
|
12.48
|
|
|
840 133.58
|
560.00
|
|
11.90
|
12.75
|
11.635
|
11.49
|
12.73
|
12.54
|
|
|
510 250.25
|
597.00
|
|
10.65
|
11.56
|
11.20
|
10.60
|
11.41
|
11.34
|
|
|
405 808.09
|
753.00
|
|
10.91
|
11.50
|
11.35
|
11.11
|
11.48
|
11.185
|
|
|
269 675.13
|
419.00
|
|
10.90
|
11.45
|
11.92
|
10.98
|
11.92
|
11.19
|
|
|
395 830.58
|
641.00
|
|
11.30
|
12.40
|
12.18
|
11.71
|
12.24
|
12.085
|
|
|
875 068.14
|
1 080.00
|
|
11.81
|
12.16
|
11.18
|
11.18
|
11.93
|
11.80
|
|
|
465 897.61
|
555.00
|
|
10.90
|
11.80
|
11.75
|
10.96
|
11.75
|
11.28
|
|
|
523 244.17
|
769.00
|
|
11.35
|
12.30
|
12.09
|
11.25
|
12.09
|
11.725
|
|
|
286 112.20
|
517.00
|
|
11.57
|
12.40
|
11.93
|
11.53
|
12.32
|
11.58
|
|
|
538 087.11
|
753.00
|
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded by leading experts in psychiatry and neuroscience, dedicated to addressing significant unmet medical needs in central nervous system (CNS) disorders. The firm’s proprietary discovery platform-leveraging optogenetics, spatial transcriptomics (STARmap) and circuit-based neuroscience-aims to identify and modulate the specific neural circuits underlying diseases. Their lead candidate, ML-007C-MA (an M/M muscarinic agonist co-formulated with a peripherally acting anticholinergic), is currently in Phase 2 development for indications including schizophrenia and Alzheimer’s disease psychosis.
The company is headquartered in Redwood City, California, and recently completed a large Series D financing of US $372.5 million to advance its pipeline.
Показать все Скрыть